API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Ocrevus (ocrelizumab) is an investigational twice-yearly, 10-minute subcutaneous injection, humanised monoclonal antibody designed to target CD20-positive B cells to treat patients with progressive and relapsing forms of MS.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023